BIT225 May have a broader role in limiting HIV-1 infection
Filed with ASX · · 2 pages · English
Earlier from Biotron
- Biotron compounds tested for activity against Zika virus
- Interim HCV genotype 3 data from BIT225-008 study
- Annual Report to Shareholders
Later from Biotron
- Phase 2 Hepatitis C Trial Success
- Trading halt
- $1.5 Million R&D Tax Rebate
- Biotron compounds demonstrate activity against Zika virus
- Zika Virus Program Update
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron